Authors
Chekhonin E.S.1, Pavlovskiy O.A.1, 2
1 Pirogov National Medical and Surgical Center, Moscow
2 Institute of Advanced Training of Physicians
Abstract
Diabetic retinopathy is one of the most severe complications of diabetes mellitus, requiring the participation of doctors of various specialties: endocrinologists, diabetologists, therapists, cardiologists, surgeons, anesthesiologists and others.
The task of an ophthalmologist is to identify pathological changes in the eye associated with diabetes mellitus and prescribe appropriate treatment.
There are three main methods for treating diabetic retinopathy:
· laser coagulation of the retina;
· intravitreal injections of anti-VEGF and glucocorticoids;
· vitreoretinal surgery.
This literature review examines the use of vascular endothelial growth factor inhibitors in the treatment of diabetic retinopathy. In particular, it discusses the most relevant drugs, the most important studies on the therapy of DR and diabetic macular edema, as well as a post hoc analysis of these studies. In addition, the role of these drugs in the therapy of refractory DME is discussed.
Keywords: Anti-VEGF, diabetic macular edema, diabetic rethinopathy.
References
1. Chekhonin E.S., Fayzrakhmanov R.R., Shishkin M.M., Kalanov M.R. Role of inhibition of angiogenesis in patients with diabetic retinopathy. Fyodorov Journal of Ophthalmic Surgery. 2022;4: 85–91. doi: 10.25276/0235-4160-2022-4-85-91 (In Russ.)
2. Chekhonin ES, Fayzrakhmanov RR, Sukhanova AV, Bosov ED. Anti-VEGF therapy for diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(4):136 142. (In Russ.)
3. Chekhonin E.S. Anti-VEGF for diabetic retinopathy: new perspectives. Bulletin of Pirogov National Medical & Surgical Center. 2022;17(4,supplement):54-56. (In Russ.)
4. Fayzrakhmanov R.R., Kalinin M.E., Pavlovsky O.A., Chekhonin E.S., Sekhina O.L. Modern concept of neovascular glaucoma (review) // Ophthalmology Reports. – 2023. – Vol. 16. – N. 3. – P. 99-108. (In Russ.)
5. The change in the thickness of the central zone of the retina after vitrectomy due to rhegmatogenous detachment of the retina using silicone tamponade / R. R. Faizrakhmanov, A. V. Sukhanova, O. A. Pavlovskii [i dr.] // Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova. – 2020. – T. 15, № 2. – S. 89-91. – DOI 10.25881/BPNMSC. 2020.32.27.015. (In Russ.)
6. Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164-2172.
7. Kanda A, Noda K, Saito W, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. https://doi.org/10.1038/srep17946
8. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744-758. https:// doi.org/10.1016/j.cell.2014.01.043
9. Yule Xu, Ao Rong, Yanlong Bi, Wei Xu. Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. https://doi.org/10.1155/2016/2143082
10. Tadayoni R, Sararols L, Weissgerber G. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. https://doi.org/ 10.1159/000513048
11. Corradetti G, Corvi F, Nguyen TV, Sadda SR. Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. Ophthalmol Retina. 2020;4(8):757-759. https://doi.org/10.1016/j.ophtha. 2019.12.031
12. Dugel PU. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99. https://doi.org/10.1016/j. ophtha.2020.06.028
13. Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies, May 1—7, 2021, ARVO, Poster.
14. Heier, J.S.; Khanani, A.M.; Quezada Ruiz, C.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740.
15. Wykoff, C.C.; Abreu, F.; Adamis, A.P.; Basu, K.; Eichenbaum, D.A.; Haskova, Z.; Lin, H.; Loewenstein, A.; Mohan, S.; Pearce, I.A.; et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet 2022, 399, 741–755.
16. Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393-401. https://doi.org/10.2147/OPTH.S128509
17. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022
18. Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321(19):1880-1894. https://doi.org/10.1001/jama.2019.5790
19. Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88-97. https://doi.org/10.1097/ IAE.0000000000002110
20. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-568. https://doi.org/10.1001/jamaophthalmol.2017.0821
21. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152. https://doi.org/10.1001/archophthalmol.2012.1043
22. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367-374. https://doi.org/10.1016/j.ophtha.2014.08.048
23. Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.
24. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. https://doi.org/10.1016/ j.ophtha.2016.07.032
25. Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3:1067-1075. https://doi.org/10.1016/j.oret.2019.06.005
26. Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. https://doi.org/10.1016/j.ophtha.2019.03.040
27. MJ E. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.
28. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636-643. https://doi.org/10.1097/ICU.0000000000000424
29. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Costeffectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18-29. https://doi.org/10.7326/M13-0768
30. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular-thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for center-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257-269. https://doi.org/10.1001/jamaophthalmol.2017.6565
31. Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258-267. https://doi.org/10.3928/23258160-20160229-09
32. Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498
33. Spencer DB, Protopsaltis NJ, Chao DL. New pharmacotherapies for diabetic retinopathy. Ann Eye Sci. 2018;3(43):1-13. https://doi.org/10.21037/aes.2018.08.02
34. Stewart MW. Future treatments of diabetic retinopathy: pharmacotherapeutic products under development. Eur Med J Diabetes. 2017;5(1):93-103.
35. Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594-1608. https://doi.org/10.1007/s00125-016-3974-8
36. Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond). 2015;29(4):534-541. https://doi.org/10.1038/eye.2014.338
37. Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016; 36(7):1292-1297. https://doi.org/10.1097/IAE.0000000000000876
38. Hanhart J, Chowers I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol. 2015;6(1):44-50. https://doi.org/10.1159/000375230
39. Ashraf M, Souka AA, ElKayal H. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases with Non-Response to Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(3):230-236. https://doi.org/10.3928/23258160-20170301-06
